We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Inovio's new Website Supports Novel Gene Expression Technology
News

Inovio's new Website Supports Novel Gene Expression Technology

Inovio's new Website Supports Novel Gene Expression Technology
News

Inovio's new Website Supports Novel Gene Expression Technology

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Inovio's new Website Supports Novel Gene Expression Technology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Inovio Biomedical Corporation, which is focused on the development of DNA vaccines and a solid tumor ablation therapy, announced that it has launched the website www.GeneSwitch.com to provide extensive technical information on Inovio’s gene regulation technology that can allow researchers to regulate, via administration of an orally available compound, the intensity and duration of gene expression from genes delivered to cells or animals.

The GeneSwitch® gene regulation technology is currently licensed for research purposes to Bayer Schering Pharma AG, GlaxoSmithKline, Organon, Senomyx, Wyeth, and Genzyme and is available in a kit form for academic research from Invitrogen.

“The GeneSwitch® regulation system used in combination with the efficient transfection observed using our proprietary electroporation technology is an attractive and convenient way to achieve gene delivery and then control resulting gene expression,” noted Avtar Dhillon, president and CEO of Inovio.

“This total solution would be particularly useful for research purposes and could potentially be used to treat protein deficiency diseases such as anemia, which results from erythropoietin (EPO) deficiency, and hemophilia, which results from factor IX deficiency.”

Advertisement